Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK H FLEISCHMAN

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1215975867
CMS profile
55661
Location
LEAWOOD, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$13,055.53

121 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK H FLEISCHMAN

NPI 1215975867 · CMS profile ID 55661

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

LEAWOOD, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215975867?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK H FLEISCHMAN, NPI 1215975867, CMS profile ID 55661. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215975867?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MARK H FLEISCHMAN, NPI 1215975867, CMS profile ID 55661. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215975867?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MARK H FLEISCHMAN, NPI 1215975867, CMS profile ID 55661, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1215975867?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

121 matching records · $13,055.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 121 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 121.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $25.5509/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735749 CMS
E.R. Squibb & Sons, L.L.C. $21.0309/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456350 CMS
Almirall LLC $18.9909/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120641946 CMS
Novartis Pharmaceuticals Corporation $27.5108/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086873091 CMS
ABBVIE INC. $24.3908/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735747 CMS
E.R. Squibb & Sons, L.L.C. $15.9108/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456338 CMS
E.R. Squibb & Sons, L.L.C. $20.1408/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456353 CMS
Dermavant Sciences, Inc. $24.0208/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127866520 CMS
LEO Pharma Inc. $23.9208/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152629919 CMS
Regeneron Healthcare Solutions, Inc. $19.5308/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114048635 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.9108/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117920763 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $29.4407/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152178960 CMS
E.R. Squibb & Sons, L.L.C. $11.7007/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456311 CMS
ABBVIE INC. $2.3907/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735745 CMS
ABBVIE INC. $4.6807/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735743 CMS
Organogenesis Inc. $144.5507/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145427639 CMS
ABBVIE INC. $50.0007/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103150349 CMS
Arcutis Biotherapeutics, Inc. $12.3007/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062165 CMS
E.R. Squibb & Sons, L.L.C. $20.4007/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456304 CMS
Incyte Corporation $19.1607/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141264151 CMS
Novartis Pharmaceuticals Corporation $19.7707/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086873089 CMS
GENZYME CORPORATION $24.4707/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139719228 CMS
Arcutis Biotherapeutics, Inc. $6.7507/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062163 CMS
Regeneron Healthcare Solutions, Inc. $26.5806/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114048633 CMS
Arcutis Biotherapeutics, Inc. $12.6506/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062147 CMS
Arcutis Biotherapeutics, Inc. $3.7406/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062161 CMS
Novartis Pharmaceuticals Corporation $21.4806/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086873085 CMS
ABBVIE INC. $13.9206/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735741 CMS
Arcutis Biotherapeutics, Inc. $10.0806/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062149 CMS
Arcutis Biotherapeutics, Inc. $16.5606/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062159 CMS
ABBVIE INC. $27.5206/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735739 CMS
Arcutis Biotherapeutics, Inc. $3.8406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062155 CMS
ConvaTec Inc. $43.3206/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151373880 CMS
ABBVIE INC. $16.5006/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735737 CMS
E.R. Squibb & Sons, L.L.C. $107.4106/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456296 CMS
Arcutis Biotherapeutics, Inc. $9.9406/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062157 CMS
E.R. Squibb & Sons, L.L.C. $22.1205/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456288 CMS
Lilly USA, LLC $17.1305/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135116917 CMS
Incyte Corporation $16.0805/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141258097 CMS
ABBVIE INC. $34.4705/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735735 CMS
E.R. Squibb & Sons, L.L.C. $24.2205/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456292 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $11.6305/09/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155489795 CMS
Arcutis Biotherapeutics, Inc. $11.4805/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062151 CMS
ABBVIE INC. $17.2804/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735733 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $13.4204/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153813668 CMS
E.R. Squibb & Sons, L.L.C. $120.4704/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101456254 CMS
Genentech USA, Inc. $14.8904/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133062337 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $83.9404/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153813666 CMS
Arcutis Biotherapeutics, Inc. $14.6104/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121062153 CMS
ABBVIE INC. $26.8204/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735731 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,268.16 89
PY2020 $827.23 48
PY2021 $854.20 31
PY2022 $1,812.24 75
PY2023 $2,636.21 100
PY2024 $13,055.53 121
PY2025 $2,005.18 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $512,168.36 51
PY2024 Principal investigator $418,647.87 47
PY2023 Recipient $15,800.00 1
PY2023 Principal investigator $19,749.84 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,147.05 12/31/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER SPECIALISTS LLC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533663
Principal investigator 1 ABBVIE INC. $3,330.00 12/30/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202532200
Principal investigator 1 ABBVIE INC. $3,330.00 12/30/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202532202
Principal investigator 1 Amgen Inc. $2,500.00 12/24/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER CENTER OF LEES SUMMIT
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640707
Principal investigator 1 ABBVIE INC. $32,232.00 12/04/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528050
Principal investigator 1 ABBVIE INC. $6,768.25 12/04/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202528052
Principal investigator 1 ABBVIE INC. $8,787.45 12/04/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528056
Principal investigator 1 SANOFI US SERVICES INC. $2,700.00 11/13/2025 Non-covered Recipient Entity
Dermatology Skin Cancer Specialists PA
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226129141
Principal investigator 1 ABBVIE INC. $1,847.55 11/05/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522275
Principal investigator 1 ABBVIE INC. $33,787.40 11/05/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522363
Principal investigator 1 ABBVIE INC. $3,000.00 11/04/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520587
Principal investigator 1 ABBVIE INC. $18,927.75 11/04/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202521239
Principal investigator 1 SANOFI US SERVICES INC. $5,757.75 10/16/2025 Non-covered Recipient Entity
Dermatology Skin Cancer Specialists PA
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226129148
Principal investigator 1 ABBVIE INC. $1,920.45 10/09/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515585
Principal investigator 1 ABBVIE INC. $12,333.30 10/09/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202515587
Principal investigator 1 ABBVIE INC. $13,366.80 10/09/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515589
Principal investigator 1 SANOFI US SERVICES INC. $1,932.60 09/25/2025 Non-covered Recipient Entity
Dermatology Skin Cancer Specialists PA
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226129136
Principal investigator 1 ABBVIE INC. $15,736.20 09/04/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509532
Principal investigator 1 ABBVIE INC. $592.05 09/03/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202507946
Principal investigator 1 ABBVIE INC. $7,079.70 09/03/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202507948
Principal investigator 1 Eli Lilly and Company $21,395.00 08/20/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER SPECIALISTS LLC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187879839
Principal investigator 1 ABBVIE INC. $39,721.05 08/06/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502679
Principal investigator 1 ABBVIE INC. $1,847.55 08/06/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502681
Principal investigator 1 ABBVIE INC. $15,367.65 08/05/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501460
Principal investigator 1 ABBVIE INC. $2,071.65 08/05/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501462
Principal investigator 1 SANOFI US SERVICES INC. $9,510.75 07/10/2025 Non-covered Recipient Entity
Dermatology Skin Cancer Specialists PA
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226129132
Principal investigator 1 ABBVIE INC. $1,920.45 07/08/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497362
Principal investigator 1 ABBVIE INC. $22,712.80 07/02/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496035
Principal investigator 1 ABBVIE INC. $6,655.80 07/02/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202496043
Principal investigator 1 ABBVIE INC. $3,782.80 06/03/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489669
Principal investigator 1 ABBVIE INC. $6,950.10 06/03/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489671
Principal investigator 1 ABBVIE INC. $1,847.55 05/07/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482959
Principal investigator 1 ABBVIE INC. $14,087.65 05/07/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482961
Principal investigator 1 ABBVIE INC. $16,341.75 05/07/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202483043
Principal investigator 1 ABBVIE INC. $2,078.40 05/07/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483045
Principal investigator 1 Eli Lilly and Company $1,500.00 04/25/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER SPECIALISTS LLC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187879841
Principal investigator 1 SANOFI US SERVICES INC. $5,629.50 04/10/2025 Non-covered Recipient Entity
Dermatology Skin Cancer Specialists PA
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226129130
Principal investigator 1 ABBVIE INC. $18,842.55 04/03/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202468959
Principal investigator 1 ABBVIE INC. $1,981.20 04/03/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202468964
Principal investigator 1 ABBVIE INC. $20,959.20 04/03/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202468967
Principal investigator 1 ABBVIE INC. $32,661.20 03/07/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460793
Principal investigator 1 ABBVIE INC. $12,130.95 03/07/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202460798
Principal investigator 1 ABBVIE INC. $2,033.85 03/07/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202460802
Principal investigator 1 ABBVIE INC. $1,981.20 02/06/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202448239
Principal investigator 1 ABBVIE INC. $12,830.25 02/06/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202449432
Principal investigator 1 ABBVIE INC. $2,391.60 02/06/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202449466
Principal investigator 1 ABBVIE INC. $13,344.95 02/06/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202449471
Principal investigator 1 SANOFI US SERVICES INC. $10,508.40 01/14/2025 Non-covered Recipient Entity
Dermatology Skin Cancer Specialists PA
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226129121
Principal investigator 1 SANOFI US SERVICES INC. $5,653.00 01/14/2025 Non-covered Recipient Entity
Dermatology Skin Cancer Specialists PA
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226129126
Principal investigator 1 Amgen Inc. $24,461.86 01/13/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER CENTER OF LEES SUMMIT
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246640709
Principal investigator 1 ABBVIE INC. $1,891.40 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202435882